This review highlights structural diversity of antimitotic agents. In particular, we emphasized current antimitotic therapies based on modulation of microtubule dynamics. With several successful anticancer drugs on the market and numerous compounds in clinical developments, tubulin-binding agents remain among the most important categories of anticancer agents. Compounds targeting mitotic kinases and kinesins are also discussed.
Keywords: antimitotic agent, inhibitor of tubulin polymerization, microtubule-stabilizing agent, mitotic kinesin, mitotic kinase
Rights & PermissionsPrintExport